Liarozole (dihydrochloride) (Standard)

Liarozole (dihydrochloride) (Standard) is the analytical standard of Liarozole (dihydrochloride) . This product is intended for research and analytical applications. Liarozole (R75251) dihydrochloride is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA) . Liarozole dihydrochloride inhibits the cytochrome P450 (CYP26) -dependent 4-hydroxylation of RA (IC50=7 μM), resulting in increased tissue levels of RA. Liarozole dihydrochloride shows antitumoral properties[1][2][3].

Product Specifications

CAS Number

[1883548-96-6]

Product Name Alternative

R75251 (dihydrochloride) (Standard)

UNSPSC

12352005

Target

Cytochrome P450; RAR/RXR; Reference Standards

Related Pathways

Metabolic Enzyme/Protease; Others; Vitamin D Related/Nuclear Receptor

Field of Research

Cancer; Metabolic Disease; Inflammation/Immunology

Smiles

ClC1=CC(C(C2=CC=C3N=CNC3=C2)N4C=CN=C4)=CC=C1.[H]Cl.[H]Cl

Molecular Formula

C17H15Cl3N4

Molecular Weight

381.69

References & Citations

[1]Kuijpers AL, et al. The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin. Br J Dermatol. 1998;139 (3) :380-389.|[2]Lucker GP, et al. Oral treatment of ichthyosis by the cytochrome P-450 inhibitor liarozole. Br J Dermatol. 1997;136 (1) :71-75.|[3]Wouters W, et al. Effects of liarozole, a new antitumoral compound, on retinoic acid-induced inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells. Cancer Res. 1992;52 (10) :2841-2846.|[4]Pignatello MA, et al. Liarozole markedly increases all trans-retinoic acid toxicity in mouse limb bud cell cultures: a model to explain the potency of the aromatic retinoid (E) -4-[2- (5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylenyl) -1-propenyl] benzoic acid. Toxicol Appl Pharmacol. 2002; 178 (3) :186-194.|[5]Van Wauwe J, et al. Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J Pharmacol Exp Ther. 1992;261 (2) :773-779.|[6]Stearns ME, et al. Liarozole and 13-cis-retinoic acid anti-prostatic tumor activity [published correction appears in Cancer Res 1993 Dec 1;53 (23) :5831]. Cancer Res. 1993;53 (13) :3073-3077.